Bioprocessing Calculators

0 calculators tagged with “Bioprocessing”

Bioprocessing is the use of biological systems — living cells, enzymes, or microorganisms — to manufacture products of commercial value, including therapeutic proteins, vaccines, monoclonal antibodies, gene therapies, and cell therapies. It encompasses two main phases: upstream processing (cell culture and fermentation to produce the desired biological molecule) and downstream processing (purification of the product from the cell culture). Bioprocessing is governed by GMP (Good Manufacturing Practice) regulations to ensure product safety, efficacy, and consistency. The global biologics market, largely produced by bioprocessing, exceeds $400 billion annually.

All Calculators

No calculators found for this topic.

Upstream Processing

Upstream includes all steps from cell bank vial thaw to the bioreactor harvest:

  • Cell banking (master cell bank and working cell bank)
  • Seed train expansion: T-flasks → spinner flasks → bioreactor inoculum trains
  • Bioreactor culture: fed-batch (most common for mAbs), perfusion, or batch
  • Critical process parameters (CPPs): pH, temperature, dissolved oxygen (DO), agitation, nutrient feeding strategy

Bioreactor Types

  • Stirred-tank bioreactor (STR): Standard for mAb production; scales from 1 L to 20,000 L
  • Single-use bioreactor (SUB): Disposable bag system; eliminates cleaning validation; preferred for clinical and small-scale production
  • Rocking motion bioreactor (e.g., Xuri): Low shear; used for suspension and primary cell culture
  • Perfusion bioreactor: Continuous medium exchange; high cell density; used for labile proteins

Downstream Processing

Downstream purification steps typically include: centrifugation/filtration (harvest); Protein A affinity chromatography (mAb capture); viral inactivation (low pH); polishing chromatography (IEX, HIC); ultrafiltration/diafiltration (buffer exchange and concentration); formulation and fill/finish.

Critical Quality Attributes (CQAs)

Product quality is monitored throughout: purity (SEC-HPLC, electrophoresis); potency (binding assays, cell-based assays); safety (endotoxin, bioburden, viral clearance); and stability (thermal, pH, freeze-thaw stress testing).

Glossary

Upstream Processing
The cell culture phase of bioprocessing from cell banking through bioreactor production and harvest; produces the biological product (mAb, protein, virus); includes seed train expansion and bioreactor operation.
Downstream Processing
Purification of the biological product from the harvest; typically includes centrifugation, Protein A chromatography, viral inactivation, polishing steps, and UF/DF; removes impurities to meet CQA specifications.
Critical Process Parameter (CPP)
A process input (pH, DO, temperature, feed rate) whose variation affects critical quality attributes (CQAs) of the biological product; must be monitored, controlled, and kept within defined acceptable ranges.

Frequently Asked Questions

Upstream processing covers everything from cell expansion through bioreactor production to harvest — the cell culture phase that produces the biological molecule. Key steps: cell banking, seed train expansion, bioreactor operation (pH, DO, temperature, feeding control), and harvest. Downstream processing purifies the product from the culture harvest — removing cells, host cell proteins, DNA, endotoxins, and other impurities. For monoclonal antibodies: Protein A affinity capture, viral inactivation, polishing chromatography, and UF/DF concentration are standard downstream steps.

CPPs are process inputs whose variation affects critical quality attributes (CQAs) of the product. For cell culture: pH (typically controlled at 6.9–7.2 for CHO cells); dissolved oxygen (DO, usually 30–50% air saturation); temperature (36–37°C for mammalian cells); agitation rate (controls mixing and oxygen transfer but causes shear stress); CO₂ sparge rate; and nutrient feed strategy (glucose, glutamine, amino acid feeds). All CPPs are continuously monitored and controlled in production bioreactors; deviations trigger investigations and may require batch disposition decisions.

Fed-batch: the bioreactor is inoculated, cells grow with nutrients fed periodically, and the entire batch is harvested at the end (typically 10–14 days). The most common production mode for monoclonal antibodies (mAbs). Simple control; batch size fixed; final cell densities 20–40 × 10⁶ cells/mL. Perfusion: fresh medium is continuously added while spent medium is continuously removed, maintaining constant nutrient and waste levels. Cell densities can reach 100–200 × 10⁶ cells/mL. Preferred for labile products with short half-lives, continuous manufacturing, and cell therapy production. More complex control; continuous harvest; smaller bioreactor needed for same productivity.

Scaling up from lab (1–10 L) to manufacturing scale (1,000–20,000 L) requires maintaining equivalent mixing, oxygen transfer, and shear environment — but these don't scale linearly. Key challenges: oxygen transfer rate (kLa) decreases at larger scale without proportional agitation increase; shear stress from impellers damages fragile mammalian cells; CO₂ accumulation increases at large scale; mixing time increases (poor pH and nutrient homogeneity). Engineers use dimensionless numbers (Reynolds, Power number, tip speed) and oxygen transfer correlations to guide scale-up. Small-scale models (ambr, BioLector) predict large-scale performance for process characterization studies.